PL324379A1 - Stabilised phrmaceutic composition, subject to stabilisation including pretreatment of growth hormone with zinc and, possibly, with lysine or calcium ions - Google Patents

Stabilised phrmaceutic composition, subject to stabilisation including pretreatment of growth hormone with zinc and, possibly, with lysine or calcium ions

Info

Publication number
PL324379A1
PL324379A1 PL96324379A PL32437996A PL324379A1 PL 324379 A1 PL324379 A1 PL 324379A1 PL 96324379 A PL96324379 A PL 96324379A PL 32437996 A PL32437996 A PL 32437996A PL 324379 A1 PL324379 A1 PL 324379A1
Authority
PL
Poland
Prior art keywords
phrmaceutic
stabilisation
stabilised
lysine
possibly
Prior art date
Application number
PL96324379A
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmegaard Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL324379A1 publication Critical patent/PL324379A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL96324379A 1995-07-14 1996-06-28 Stabilised phrmaceutic composition, subject to stabilisation including pretreatment of growth hormone with zinc and, possibly, with lysine or calcium ions PL324379A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14

Publications (1)

Publication Number Publication Date
PL324379A1 true PL324379A1 (en) 1998-05-25

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96324379A PL324379A1 (en) 1995-07-14 1996-06-28 Stabilised phrmaceutic composition, subject to stabilisation including pretreatment of growth hormone with zinc and, possibly, with lysine or calcium ions

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155L (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233088T1 (en) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
DK1076703T4 (en) 1998-05-15 2011-03-28 Genentech Inc Therapeutic uses of IL-17 homologous polypeptides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897947B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
KR20080011353A (en) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 Non-aqueous injectable formulations for extended release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
ES2266187T3 (en) 2000-03-24 2007-03-01 Genentech, Inc. USE OF INSULIN FOR THE TREATMENT OF CARTILAGO DISORDERS.
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA03000073A (en) 2000-06-26 2003-09-25 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (en) 2000-08-07 2004-05-27 ネクター セラピューティックス Inhalable, spray-dried, 4-helix bundle protein powder with minimal aggregates
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2003213271B2 (en) 2002-02-25 2009-07-16 Genentech, Inc. Novel type-1 cytokine receptor GLM-R
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
KR101148657B1 (en) 2003-06-06 2012-07-05 제넨테크, 인크. Modulating the interaction between hgf beta chain and c-met
SI2784084T2 (en) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonist antibodies to IL-17A/F heterologous polypeptides
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
CA2561577A1 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
CA2584221A1 (en) 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
SI2314623T1 (en) 2005-06-21 2012-11-30 Xoma Technology Ltd IL-1beta binding antibodies and fragments thereof
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US8105585B2 (en) 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
AR059300A1 (en) 2006-02-02 2008-03-26 Trimeris Inc INHIBITING PEPTIDES OF HIV FUSION WITH IMPROVED BIOLOGICAL PROPERTIES
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
HUE031329T2 (en) * 2006-07-06 2017-07-28 Daewoong Co Ltd A stable liquid formulation of human growth hormone
AU2007333635B2 (en) 2006-12-20 2014-02-20 Xoma (Us) Llc Treatment of IL-1-beta related diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
MX2010006823A (en) 2007-12-20 2010-09-30 Xoma Technology Ltd Methods for the treatment of gout.
CN102186490B (en) * 2008-08-15 2015-07-29 硬木药品公司 Be applicable to the stable solid preparation of the guanylate cyclase-C receptor agonist polypeptide of oral administration
WO2010027404A2 (en) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2777717C (en) 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
CA2787208C (en) 2010-01-15 2017-06-06 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
TR201711271T4 (en) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Treatments for Gastrointestinal Disorders
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
PL2603232T3 (en) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
KR102050609B1 (en) * 2011-06-02 2019-11-29 박스알타 인코퍼레이티드 Formulations of recombinant furin
CN104053449B (en) 2011-08-17 2016-12-07 硬木药品公司 The treatment of gastrointestinal tract disease
SI3091029T1 (en) 2011-10-31 2023-03-31 F. Hoffmann - La Roche Ag Anti-il13 antibody formulations
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (en) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート Humanized antibody
JP6448614B2 (en) 2013-03-15 2019-01-09 ベス イスラエル デアコネス メディカル センター インコーポレイテッド Methods and compositions for generation and use of conformation specific antibodies
CN111518199A (en) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6822839B2 (en) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート Modified therapeutic agents and their compositions
ES2845924T3 (en) 2013-10-15 2021-07-28 Scripps Research Inst T-cell switches with peptide chimeric antigen receptors and their uses
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
EP4333872A1 (en) 2021-05-06 2024-03-13 Hoba Therapeutics ApS Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
AU715997B2 (en) 2000-02-17
EP0839049A1 (en) 1998-05-06
NO980155D0 (en) 1998-01-13
BR9609741A (en) 1999-03-16
KR19990028981A (en) 1999-04-15
HUP9802287A3 (en) 2000-10-30
CN1190897A (en) 1998-08-19
NO980155L (en) 1998-01-13
JPH11509212A (en) 1999-08-17
IL122583A0 (en) 1998-06-15
WO1997003692A1 (en) 1997-02-06
ZA965368B (en) 1997-01-14
CZ9498A3 (en) 1998-06-17
AU6353496A (en) 1997-02-18
MX9800358A (en) 1998-07-31
CA2226523A1 (en) 1997-02-06
HUP9802287A2 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
PL324379A1 (en) Stabilised phrmaceutic composition, subject to stabilisation including pretreatment of growth hormone with zinc and, possibly, with lysine or calcium ions
PL321590A1 (en) Compounds capable to cause liberation of the growth hormone
AU4792193A (en) Composition of low type iii content human placental collagen
HUP9802580A3 (en) Compounds with growth hormone releasing properties
ZA945462B (en) Benzo-fused lactams promote release of growth hormone
EP0669830A4 (en) Substituted dipeptide analogs promote release of growth hormone.
ZA949899B (en) Heterocyclic-fused lactams promote release of growth hormone
AU6772996A (en) 2-acylaminopropanamides as growth hormone secretagogues
IL129555A0 (en) Methods and compositions for stimulating neurite growth
IL122371A0 (en) Compounds with growth hormone releasing properties
AU9471598A (en) Treatment of congestive heart failure with growth hormone secretagogues
HK1028051A1 (en) Treatment of insulin resistance with growth hormone secretagogues
AU6724496A (en) 2-acylaminopropanamines as growth hormone secretagogues
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
IL101587A0 (en) Biologically active peptide composition and uses therefor
EP0550035A3 (en) Composition of stabilized fibroblast growth factor
PL319382A1 (en) Polypeptidic compounds containing d-2-alkylotryptophane capable to promote liberation of growth hormone
PH31558A (en) Release controlled implantable somatotropin composition.
EP1126854A4 (en) Benzoazepines and analogs thereof useful as growth hormone secretagogues
GB9823422D0 (en) Naptho-fused lactams promate release of growth hormone
AU1304895A (en) Peptides to overcome inhibition of nerve growth
AU7609298A (en) Treatment of heart failure with growth hormone
AU7476494A (en) Use of n-methyl-aspartic acid for enhancing growth and altering body composition
EP0796095A4 (en) Methods of inhibiting growth hormone effects
EP0804543A4 (en) Plant growth stimulating composition